310 related articles for article (PubMed ID: 22484189)
21. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G
Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629
[TBL] [Abstract][Full Text] [Related]
22. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
Koseła-Paterczyk H; Rutkowski P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
[TBL] [Abstract][Full Text] [Related]
23. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
Touati N; Schöffski P; Litière S; Judson I; Sleijfer S; van der Graaf WT; Italiano A; Isambert N; Gil T; Blay JY; Stark D; Brodowicz T; Marréaud S; Gronchi A
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):448-454. PubMed ID: 29550245
[TBL] [Abstract][Full Text] [Related]
24. [Adjuvant chemotherapy of adults soft tissue sarcomas].
Bui-Nguyen B; Italiano A; Delva F; Toulmond M
Bull Cancer; 2010 Jun; 97(6):673-8. PubMed ID: 20547481
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas.
Yanagawa T; Shinozaki T; Watanabe H; Saito K; Raz A; Takagishi K
Exp Cell Res; 2012 Apr; 318(7):800-8. PubMed ID: 22326461
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
Chawla SP; Staddon AP; Baker LH; Schuetze SM; Tolcher AW; D'Amato GZ; Blay JY; Mita MM; Sankhala KK; Berk L; Rivera VM; Clackson T; Loewy JW; Haluska FG; Demetri GD
J Clin Oncol; 2012 Jan; 30(1):78-84. PubMed ID: 22067397
[TBL] [Abstract][Full Text] [Related]
27. Anti-angiogenic therapy, a new player in the field of sarcoma treatment.
Versleijen-Jonkers YM; Vlenterie M; van de Luijtgaarden AC; van der Graaf WT
Crit Rev Oncol Hematol; 2014 Aug; 91(2):172-85. PubMed ID: 24613529
[TBL] [Abstract][Full Text] [Related]
28. The role of tumor vascularisation in benign and malignant cardiovascular neoplasms: a comparison of cardiac myxoma and sarcomas of the pulmonary artery.
Gaumann A; Strubel G; Bode-Lesniewska B; Schmidtmann I; Kriegsmann J; Kirkpatrick CJ
Oncol Rep; 2008 Aug; 20(2):309-18. PubMed ID: 18636191
[TBL] [Abstract][Full Text] [Related]
29. Granular cell tumors of the urethra.
Evmorfopoulos K; Tzortzis V; Vlachostergios PJ
Cancer Treat Res Commun; 2023; 35():100695. PubMed ID: 36940531
[TBL] [Abstract][Full Text] [Related]
30. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
[TBL] [Abstract][Full Text] [Related]
31. Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?
Kasper B; Ho AD; Egerer G
Oncology; 2005; 68(2-3):115-21. PubMed ID: 15886503
[TBL] [Abstract][Full Text] [Related]
32. Ifosfamide in the treatment of soft tissue sarcomas.
Connelly EF; Budd GT
Semin Oncol; 1996 Jun; 23(3 Suppl 6):16-21. PubMed ID: 8677442
[TBL] [Abstract][Full Text] [Related]
33. Trabectedin in soft tissue sarcomas.
Petek BJ; Loggers ET; Pollack SM; Jones RL
Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 clinical trials for sarcomas: the cutting edge.
Subbiah V; Kurzrock R
Curr Opin Oncol; 2011 Jul; 23(4):352-60. PubMed ID: 21519259
[TBL] [Abstract][Full Text] [Related]
35. Sarcomas of the skin in the elderly.
Mentzel T
Clin Dermatol; 2011; 29(1):80-90. PubMed ID: 21146736
[TBL] [Abstract][Full Text] [Related]
36. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
Yoon C; Chang KK; Lee JH; Tap WD; Hart CP; Simon MC; Yoon SS
Oncotarget; 2016 Jul; 7(28):42844-42858. PubMed ID: 27374091
[TBL] [Abstract][Full Text] [Related]
37. Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future.
Morgan SS; Cranmer LD
Curr Oncol Rep; 2011 Aug; 13(4):331-49. PubMed ID: 21633784
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous Malignant Peripheral Nerve Sheath Tumor.
Luzar B; Falconieri G
Surg Pathol Clin; 2017 Jun; 10(2):337-343. PubMed ID: 28477884
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in the management of cutaneous lymphomas.
Belloni B; Johansen N; Glass LF; Dummer R
Semin Oncol; 2012 Apr; 39(2):150-62. PubMed ID: 22484187
[TBL] [Abstract][Full Text] [Related]
40. Systemic adjuvant chemotherapy for soft tissue sarcomas.
Zalupski MM; Baker LH
Hematol Oncol Clin North Am; 1995 Aug; 9(4):787-800. PubMed ID: 7490241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
